Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Composition of Konecranes Plc’s Shareholders’ Nomination Board

KONECRANES PLC STOCK EXCHANGE RELEASE September 9, 2024 at 5:00 PM EEST   Composition of Konecranes Plc’s Shareholders’ Nomination Board   Konecranes has a Shareholders' Nomination Board which prepares proposals to the Annual General Meeting, and, if necessary, to an Extraordinary General Meeting, for the election and remuneration of the members of the Board of Directors and to identify potential Board member candidates.   The Shareholders' Nomination Board is comprised of one member appointed by each of the four largest shareholders of Konecranes Plc. The shareholders

Dicot Pharma announces last day of trading in BTU and first day of trading for warrants series TO 6

Uppsala, Sweden, September 9, 2024. Dicot Pharma AB ("Dicot Pharma") announces that the rights issue that ended on August 27, 2024, will be registered with the Swedish Companies Registration Office this week and paid subscribed units (BTU) will be replaced with shares and warrants of series TO6. The last day of trading in BTU is September 11, 2024, and the stop date at Euroclear is September 13, 2024. The new shares and warrants series of TO 6 are expected to be booked into each shareholder's VP account/custody account on September 17, 2024. The first day of trading in warrants series of TO 6

Stora Enso appoints Pasi Kyckling as acting CFO

STORA ENSO OYJ INVESTOR NEWS 9 September 2024 at 16:30 EESTStora Enso has appointed Pasi Kyckling as acting CFO until Niclas Rosenlew starts in his position as new CFO. Pasi will hold the role of acting CFO from 1 November 2024 until Niclas joins Stora Enso, at the latest in January 2025. As announced in May, Stora Enso’s current CFO Seppo Parvi will assume a role with a company outside of the forest industry.Pasi Kyckling is currently Group Transformation Officer at Stora Enso, steering the Group’s transformative initiatives to improve profitability and cash flow. He joined Stora Enso in

BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference

Bergen, Norway, September 9, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference held in New York City, September 9-11, 2024.    Chief Executive Officer Martin Olin will provide a business update including the ongoing BGBC016 clinical study in 1st line Non-Small Cell Lung Cancer with STK11 mutations.   The presentation used at the conference is available in the

Enzymatica publishes supplementary prospectus

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (“Enzymatica” or “Company”) has issued a supplement (the “Supplementary Prospectus”) in addition to the EU growth prospectus that has been approved and registered by the Swedish Financial

Acquisitions of own shares in Evolution AB (publ)

Evolution AB (publ) (“Evolution”) has, during the period 02 September - 06 September acquired a total of 119,600 own shares within the framework of the repurchase programme introduced by the board of directors to improve the capital structure of Evolution by reducing the capital, and thereby creating added shareholder value.The repurchase programme, which Evolution announced on 18 July 2024, is being implemented in accordance with the EU Market Abuse Regulation No 596/2014 (“MAR”) and Commission Delegated Regulation No 2016/1052 (“Safe Harbour Regulation”). During the period 02 September

PLAGAZI ANNOUNCES CHANGES TO BOARD OF DIRECTORS

Johan Mandelius replaces Valerie Dujardin as Chairman of the Board of Directors, while Anders Hellsten joins the Board as a Member. Additionally, former Chairman and Member of the Board Torsten Granberg is stepping down from the Board of Directors.Johan Mandelius has extensive experience in change management in strategy, business and operational development, especially in international organisations. Johan is an expert in navigating complex change, leading large projects and programmes, and establishing and leading high-performing teams. He is known for his analytical skills and drive to

Vestas secures its first U.S. offshore order with 810 MW Empire Wind 1 project

News release from Vestas-American Wind TechnologyPortland, 9 September 2024 Vestas has secured an 810 MW offshore order from Equinor to power New York’s Empire Wind 1 offshore wind project. The order includes 54 V236-15.0 MW turbines and marks Vestas’ first order in the U.S. for an offshore platform and its industry-leading, type-certified V236-15.0 MW turbine. The order includes supply, delivery, and commissioning of the turbines, as well as a five-year comprehensive service agreement, designed to ensure optimised performance of the asset followed by a long-term service support

Tokmanni Group Corporation: Managers' Transactions – Tapio Arimo

Tokmanni Group Corporation        Managers' Transactions        9 September 2024 at 3:30 pmPerson subject to the notification requirementName: Tapio ArimoPosition: Chief Financial OfficerIssuer: Tokmanni Group OyjLEI: 743700VMG6KWF0FW1560Notification type: INITIAL NOTIFICATIONReference number: 76845/5/8 Transaction date: 2024-09-05Venue: OMXHInstrument type: SHAREISIN: FI4000197934Nature of transaction: ACQUISITION Transaction details(1): Volume: 4888 Unit price: 10.6 EUR(2): Volume: 112 Unit price: 10.6 EUR Aggregated transactions (2):Volume: 5000 Volume

CORRECTION TO STOCK EXCHANGE RELEASE: Mandatum plc: Managers' Transactions (Niemisvirta)

Mandatum plc, Stock exchange release / Managers’ transactions, 9 September 2024 at 3:30 p.m. EEST Correction to Mandatum plc’s (business ID 3355142-3) stock exchange release regarding the Managers’ Transactions on 6 September 2024 at 15:00. In the original notification, it was erroneously stated that the transaction was carried out in connection with life insurance. Below is the correct notification:Mandatum Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Petri Niemisvirta Position: Chief

CORRECTION TO STOCK EXCHANGE RELEASE: Mandatum plc: Managers' Transactions (Vieraankivi)

Mandatum plc, Stock exchange release / Managers’ transactions, 9 September 2024 at 3:30 p.m. EESTCorrection to Mandatum plc’s (business ID 3355142-3) stock exchange release regarding the Managers’ Transactions on 6 September 2024 at 15:00. In the original notification, it was erroneously stated that the transaction was carried out in connection with life insurance. Below is the correct notification: Mandatum Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Petri Vieraankivi Position: Other senior

BioStock has published an article on the approved OMPD for CS1 in the EU including an interview of Cereno Scientific’s CEO Sten R. Sörensen

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that an article by BioStock has been published containing an interview with Cereno’s CEO, Sten R. Sörensen, on the newly granted Orphan Medicinal Product Designation (OMPD) for CS1 in rare disease Pulmonary Arterial Hypertension (PAH).Read the article here .   For further information, please contact: Henrik Westdahl, Director IR &

Notice of Extraordinary General Meeting at Clinical Laserthermia Systems

The shareholders of Clinical Laserthermia Systems AB, 556705-8903, are hereby invited to an Extraordinary General Meeting on Monday, October 21, 2024, at 10:00 AM at Scheelevägen 4, Medicon Village, Lund.Right to participate and registration Shareholders wishing to participate in the meeting must: · Be registered in the shareholders' register maintained by Euroclear Sweden AB by Friday, October 11, 2024, and · Notify the company no later than Tuesday, October 15, 2024, in writing to Clinical Laserthermia Systems AB, Medicon Village, Scheelegatan 2, 223 63 Lund. Notification can

President and CEO Jonas Gustavsson is leaving AFRY AB (publ)

After eight years as President and CEO, Jonas Gustavsson is leaving AFRY to pursue other opportunities outside the company. A recruitment process to find a successor will start immediately. Jonas Gustavsson will remain in his current role until a successor has been appointed or at the latest until 31 March 2025.“Under Jonas Gustavsson’s leadership, AFRY has doubled its turnover and taken a leading position in the transition towards a more sustainable society. The acquisition of and merger with Finnish Pöyry Plc has been a crucial step on this journey. AFRY is well positioned for further

CLS announces proposal for changes to the Board of Directors

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announced that the Chairman of the Board of Directors Hans von Celsing and, Board member, Paolo Raffaelli, will resign from the Board of Directors at their own request. Peter Max and Peter Mantas are proposed as new members of the Board, the former of whom is also proposed as the new chairman of CLS. Furthermore, it is proposed that Lars Erik Eriksson, Sandy Brandmeier and Marika Crohns  remain  as members of the Board. The Nomination Committee supports this proposal. Notice of an Extraordinary General

Sinch mandates banks to explore issue of senior unsecured notes

Stockholm, Sweden – 9 September 2024 – Sinch AB (publ), which is pioneering the way the world communicates through its Customer Communications Cloud, today announces that the company has mandated Danske Bank, SEB and Svenska Handelsbanken as Joint Lead Managers to explore the possibility of issuing new SEK denominated senior unsecured notes under the recently established MTN program. The transaction is expected to be launched in the near future, subject to market conditions, and will further diversify Sinch’s sources of funding. Proceeds will be used to refinance outstanding debt and will

Root Signals raises $2.8M to accelerate GenAI business adoption by having AI watch AI

Despite global hype for GenAI, most businesses have so far failed to take their GenAI prototypes from experimentation to production. Root Signals has developed an AI control platform based on LLM judges to make GenAI outputs measurable and reliable. When GenAI applications and agents are built on a stable foundation from the start, companies are better positioned to maximize their long-term business value.Root Signals , a startup based in Helsinki and Palo Alto specializing in generative AI (GenAI) measurement with LLM-as-a-judge techniques, has raised $2.8M.

BioStock: Cereno comments on EU orphan designation for CS1

Cereno Scientific has received Orphan Medicinal Product Designation in the EU for CS1 in Pulmonary Arterial Hypertension, a rare cardiovascular disease. The decision comes as the company awaits topline data from a phase II trial evaluating CS1 in PAH. BioStock spoke with Cereno’s CEO Sten R. Sörensen to get his take on why this is a key milestone for the company.Read the interview with CEO Sten R. Sörensen at biostock.se:https://www.biostock.se/en/2024/09/cereno-comments-on-eu-orphan-designation-for-cs1/This is a press release from BioStock - Connecting Innovation & Capital. https://www.

AcuCort Presents Study Results at the ISPOR Scientific Conference in Barcelona

AcuCort will participate in the ISPOR scientific conference in Barcelona on November 19, 2024. The company will present the results of the study titled "Swedish Allergists' View on the Role of Cortisone and the Formulation (Tablets or Self-Dissolving Film) for the Treatment of Acute Allergic Reactions."The study titled "Swedish Allergists' View on the Role of Cortisone and the Formulation (Tablets or Self-Dissolving Film) for the Treatment of Acute Allergic Reactions" was conducted in 2023. The study was carried out through interviews with clinically experienced allergists. The primary

Metso’s Sorocaba foundry and rubber factory in Brazil has received carbon-neutral certification

Metso Corporation’s press release on September 9, 2024, at 2:00 p.m. EESTIn July, Metso’s Sorocaba foundry and rubber factory in Brazil received carbon-neutral certification in line with PAS 2060:2014 standard from an independent third-party, BSI. The supply chain operations are pivotal to Metso’s overall CO2 footprint, with the Sorocaba foundry and rubber factories accounting for around 20% of Metso’s own operation’s CO2 emissions.    “Metso aims to achieve net zero by 2030 in its own operations, and the certification now obtained is a step towards the set goal. Carbon neutrality is

Net Asset Value(s)

MITON UK MICROCAP TRUST PLC  Miton UK MicroCap Trust plc 9th September 2024Miton UK Microcap Trust plc It is announced that at the close of business on 6th September 2024, the unaudited Net Asset Value per share of Miton UK Microcap Trust plc is: With the portfolio valued on a fair value basis: Including current period revenue to 6th September 2024                                    53.59p per ordinary share Excluding current period revenue                53.41p per ordinary share Legal

Sinch announces changes to its financial leverage policy

Stockholm, Sweden – 9 September 2024 – Sinch AB (publ), which is pioneering the way the world communicates through its Customer Communications Cloud, today announces that the Board of Directors has changed the company’s financial leverage policy. The new policy is that: · Net debt over time shall be below 2.5 times adjusted EBITDA (measured on a rolling twelve-month basis). The phrase ‘over time’ means that leverage may temporarily exceed 2.5 times adjusted EBITDA in the near term following an acquisition. Before today’s announcement, the policy was that net debt over time shall be

Panel talk about Inify’s second quarter 2024

"We are saving weeks in waiting time for patients to get the diagnosis". This and more value that Inify Laboratories can provide to its customers from day one is highlighted in this panel talk about the second quarter of 2024 with CEO Fredrik Palm, Laboratory Director Emelie Edvigsson and Ole Eikeland.Inify Laboratories continued to deliver strong growth with sales of SEK 3.6 million in the quarter – up 62% compared to Q1. By the end of June, the laboratory had been open for over a year and had diagnosed more than 1,000 patients. More details about the laboratory operations and its

There are no items matching the current filter
There are no more items matching the current filter
Back to top